Latest News

The impact of e-Therapeutics plc (AIM: ETX)  drug discovery activities has been rated World Class by the UK's National Research and Impact Assessment exercise.  More details available here.

  • British Prime Minister David Cameron and Prof. Malcolm Young, CEO of e-Therapeutics, shake hands as the Prime Minister opens e-Therapeutics’ drug discovery centre at Oxford.